We design, develop, manufacture and commercialize a broad suite of precision guided therapy tools including intravascular ultrasound, or IVUS, and fractional flow reserve, or FFR, products. We believe that these products enhance the diagnosis and treatment of coronary and peripheral vascular disease by improving the efficiency and efficacy of existing diagnostic angiograms and percutaneous coronary interventional, or PCI, and endovascular procedures in the coronary arteries or peripheral arteries and veins. We are facilitating the adoption of functional PCI, in which our FFR technology is used to help determine whether or not a stent is necessary, and IVUS is used as an adjunct to angiography to guide stent placement and optimization. We market our products to physicians, nurses and technicians who perform a variety of endovascular based coronary and peripheral interventional procedures in hospitals and to other personnel who make purchasing decisions on behalf of hospitals. Our products consist of consoles that are marketed as stand-alone units or as units that can be integrated into a variety of hospital-based interventional surgical suites called catheterization laboratories, or cath labs. We have developed customized cath lab versions of these consoles and are developing additional functionality options as part of our cath lab integration initiative. Our consoles have been designed to serve as a multi-modality platform for our phased array and rotational IVUS catheters, FFR pressure and flow wires and image-guided therapy catheters, such as the Pioneer Plus reentry device acquired from Medtronic Inc., or Medtronic, on August 30, 2013.
Company profile
Ticker
VOLC
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
SEC CIK
Corporate docs
IRS number
330928885
Latest filings (excl ownership)
15-12G
Securities registration termination
2 Mar 15
15-12G
Securities registration termination
27 Feb 15
EFFECT
Notice of effectiveness
25 Feb 15
EFFECT
Notice of effectiveness
25 Feb 15
25-NSE
Exchange delisting
17 Feb 15
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Feb 15
POS AM
Prospectus update (post-effective amendment)
17 Feb 15
POS AM
Prospectus update (post-effective amendment)
17 Feb 15
POSASR
Automatic shelf registration (post-effective amendment)
17 Feb 15
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Feb 15
Latest ownership filings
SC 13D/A
Volcano Corp
18 Feb 15
SC 13G
Volcano Corp
17 Feb 15
SC 13G
Volcano Corp
17 Feb 15
SC 13G/A
Volcano Corp
17 Feb 15
SC 13G/A
Volcano Corp
12 Feb 15
SC 13G/A
Volcano Corp
11 Feb 15
SC 13G/A
Volcano Corp
11 Feb 15
SC 13G/A
Volcano Corp
10 Feb 15
SC 13G/A
Volcano Corp
9 Feb 15
SC 13G/A
Volcano Corp
16 Jan 15
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|